METRONIDAZOLE 500 MG — DIN 02534592
METRONIDAZOLE : 500 MG · SANIS HEALTH INC · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is METRONIDAZOLE?
METRONIDAZOLE 500 MG contains METRONIDAZOLE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02534592, held by SANIS HEALTH INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 21-Dec-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is METRONIDAZOLE used for?
Trichomonal infections, hepatic and intestinal amebiasis, giardiasis, bacterial vaginosis, and serious anaerobic intra-abdominal, brain, or lung infections.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Metronidazole cost around the world?
Metronidazole is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 5 | 62 | USD███.██ |
| Saudi Arabia | public | 46 | 52 | SAR███.██ |
| South Africa | single exit price | 41 | 50 | ZAR███.██ |
| Morocco | PPV (public price) | 14 | 26 | MAD███.██ |
| United Arab Emirates | public | 13 | 18 | AED███.██ |
| Greece | producer price (ex-factory) | 16 | 16 | EUR███.██ |
| Australia | ex-manufacturer | 5 | 14 | AUD███.██ |
| Bahrain | retail (max) | 12 | 13 | BHD███.██ |
| Czechia | max producer price (ex-factory) | 5 | 9 | CZK███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| Austria | KVP (Kassenverkaufspreis) | 1 | 3 | EUR███.██ |
| Lebanon | public price (USD, Decision 119/1) | 2 | 3 | USD███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
276 pack listings across 169 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Metronidazole pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Metronidazole in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Metronidazole, across 11 DINs, of which 7 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 4 | 2 | APO-METRONIDAZOLE, APO-METRONIDAZOLE TABLETS | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-METRONIDAZOLE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | METRONIDAZOLE | Sourceable in Canada |
| MANTRA PHARMA INC | 1 | 1 | M-METRONIDAZOLE | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 1 | 1 | MINT-METRONIDAZOLE | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | METRONIDAZOLE | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 0 | MAR-METRONIDAZOLE | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 1 | 0 | FLAGYL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | HDPE bottles of 100 and 500 Capsules. |
| Storage | Store at room temperature 15°C to 30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Metronidazole |
|---|---|
| ATC code | P01AB01 |
| AHFS class | 08:30.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02534592 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2534592 |
| Brand name | METRONIDAZOLE |
| Generic / active ingredient | METRONIDAZOLE : 500 MG |
| Market authorization holder | SANIS HEALTH INC |
| Health Canada schedule | Prescription |
| ATC code | P01AB01 |
| ATC anatomical main group | P — Antiparasitic products, insecticides and repellents |
| ATC therapeutic subgroup | P01AB |
| Current status | MARKETED |
| Status date | 21-Dec-2023 |
| Original market date | 2023-12-21 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Trichomoniasis: 2g single dose or 250mg BID for 10 days. Amebiasis: 750mg TID for 5-7 days. Giardiasis: 250mg BID for 5-7 days. Bacterial Vaginosis: 500mg BID for 7 days. Anaerobic infections: 500mg q8h.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to metronidazole or nitroimidazole derivatives; active neurological disorders; history of blood dyscrasia, hypothyroidism, or hypoadrenalism.
Warnings and precautions
Carcinogenic in mice/rats. Risk of severe neurological disturbances (seizures, neuropathy). Severe hepatotoxicity in Cockayne syndrome. Avoid alcohol during and 1 day after therapy.
Is Metronidazole in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Discontinued — reported by PFIZER CANADA ULC, last seen 19 May 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
7 of 11 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-METRONIDAZOLE | 500 MG | CAPSULE | APOTEX INC | MARKETED | 02248562 |
| APO-METRONIDAZOLE TABLETS | 250 MG | TABLET | APOTEX INC | MARKETED | 00545066 |
| AURO-METRONIDAZOLE | 500 MG | CAPSULE | AURO PHARMA INC | MARKETED | 02470284 |
| M-METRONIDAZOLE | 500 MG | CAPSULE | MANTRA PHARMA INC | MARKETED | 02519755 |
| METRONIDAZOLE | 500 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | 02518767 |
| MINT-METRONIDAZOLE | 250 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02535807 |
| APO-METRONIDAZOLE | 500 MG | CAPSULE | APOTEX INC | CANCELLED PRE MARKET | 02406489 |
| APO-METRONIDAZOLE | 250 MG | TABLET | APOTEX INC | CANCELLED PRE MARKET | 02406470 |
| FLAGYL | 500 MG | CAPSULE | SANOFI-AVENTIS CANADA INC | CANCELLED PRE MARKET | 01926853 |
| MAR-METRONIDAZOLE | 500 MG | CAPSULE | MARCAN PHARMACEUTICALS INC | APPROVED | 02491370 |
2 · Same class — other molecules in ATC P01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Metronidazole | APO-METRONIDAZOLE · APO-METRONIDAZOLE TABLETS · AURO-METRONIDAZOLE · FLAGYL · +4 more | 11 | 7 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC P01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| P01AX | Atovaquone · Trimetrexate | 6 | 3 |
| P01AA | Hydroxyquinoline Derivatives | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is METRONIDAZOLE called?
The same molecule, Metronidazole, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Flagyl | Latin | Australia, Bahrain, Morocco, South Africa |
| METRONIDAMED | Latin | Australia |
| METRONIDAZOLE NORIDEM | Latin | Czechia |
| METROZAL | Latin | Morocco |
| RIAZOLE | Latin | Bahrain, Saudi Arabia |
| Suprazole | Latin | Bahrain, Saudi Arabia, South Africa |
| Anaerobex Filmtabl. | Latin | Austria |
| NIDAZOL | Latin | Morocco |
| Trichazole | Latin | South Africa |
| ANAZOL | Latin | Saudi Arabia |
| Bemetrazole | Latin | South Africa |
| Flagyl S | Latin | Australia |
| Metagyl Forte Tablets | Latin | South Africa |
| Metrobactin vet | Latin | Iceland |
| METRONIDAZOLE MYLAN | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.